论文部分内容阅读
目的 :探讨表皮生长因子受体变异体Ⅲ(epidermal growth factor receptor variantⅢ,EGFRvⅢ)和S100钙结合蛋白A9(S100 calcium binding protein A9,S100A9)在人脑胶质瘤组织中的表达水平及其相关性,以及2种蛋白表达与胶质瘤预后的关系。方法:收集重庆医科大学第二附属医院2008年1月—2015年4月收治的110例经病理确诊的新发胶质瘤标本及其临床资料。同时,收集10例非肿瘤脑组织作为对照。采用免疫组织化学法检测胶质瘤标本和对照脑组织中EGFRvⅢ和S100A9蛋白的表达水平,运用Spearman等级相关分析法分析蛋白表达与胶质瘤患者临床病理因素的相关性。随访其中75例胶质瘤患者,实访67例,采用Kaplan-Meier法对随访资料进行生存分析。结果:低级别胶质瘤(Ⅰ~Ⅱ级)中EGFRvⅢ的中高表达率为20.00%,而高级别胶质瘤(Ⅲ~Ⅳ级)中EGFRvⅢ的中高表达率为38.00%,两者差异有统计学意义(P<0.001);低级别胶质瘤(Ⅰ~Ⅱ级)中S100A9的高表达率也明显低于高级别胶质瘤(Ⅲ~Ⅳ级)中S100A9的高表达率(11.67%vs 66.00%,P<0.001)。EGFRvⅢ和S100A9蛋白表达水平之间呈明显的正相关性(r s=0.785,P<0.001)。Kaplan-Meier生存分析表明,EGFRvⅢ和S100A9蛋白均表达阳性的胶质瘤患者的预后较差(P=0.002)。结论:EGFRvⅢ和S100A9蛋白均随着胶质瘤恶性等级升高而表达增强。联合检测EGFRvⅢ和S100A9蛋白水平可以有效判断胶质瘤患者的恶性程度及预后,有助于为胶质瘤患者制定个体化的治疗方案。
Objective: To investigate the expression of S100 calcium binding protein A9 (S100A9) and epidermal growth factor receptor variantⅢ (EGFRvⅢ) in human glioma and its correlation , And the relationship between the expression of two proteins and the prognosis of glioma. Methods: A total of 110 newly diagnosed glioma specimens from the Second Affiliated Hospital of Chongqing Medical University from January 2008 to April 2015 were collected and their clinical data were collected. Meanwhile, 10 non-tumor brain tissues were collected as a control. Immunohistochemistry was used to detect the expression of EGFRvⅢ and S100A9 in glioma specimens and control brain tissues. Spearman rank correlation analysis was used to analyze the correlation between protein expression and clinicopathological factors in gliomas. Among them, 75 cases of glioma were followed up, 67 cases were interviewed, and the follow-up data were analyzed by Kaplan-Meier method. Results: The positive rates of EGFRv Ⅲ in low grade gliomas (gradeⅠ ~ Ⅱ) were 20.00%, while those in high grade gliomas (Ⅲ ~ Ⅳ grade) were 38.00%. The differences between the two groups were statistically significant (P <0.001). The high expression rate of S100A9 in low grade gliomas (grade Ⅰ ~ Ⅱ) was also significantly lower than that of S100A9 in high grade gliomas (grade Ⅲ ~ Ⅳ) (11.67% vs 66.00%, P <0.001). There was a significant positive correlation between EGFRvⅢ and S100A9 protein expression (r s = 0.785, P <0.001). Kaplan-Meier survival analysis showed that patients with positive EGFRvIII and S100A9 protein had a poorer prognosis (P = 0.002). Conclusion: The expressions of EGFRvⅢ and S100A9 protein are increased with the malignant grade of glioma. Combined detection of EGFRvIII and S100A9 protein levels can effectively determine the degree of malignancy and prognosis of patients with glioma and help to develop personalized treatment for patients with glioma.